Description:
Background:
- Medullary thyroid cancer (MTC) represents 5% of thyroid cancers and presents as a
hereditary (25% of cases) or sporadic (75% of cases) neuroendocrine malignancy.
- MTC arises from the parafollicular C-cells of the thyroid.
- Germline mutations in the rearranged during transfection (RET) proto-oncogene occur in
virtually all of hereditary MTC cases, and somatic RET mutations occur in 50% of
sporadic cases.
- Drugs targeting RET kinase such as vandetanib and cabozantinib have shown efficacy in
the treatment of advanced or metastatic MTC, however, more effective RET inhibitors are
needed for previously untreated patients as well as patients who have become refractory
to other molecular targeted therapeutics (MTTs).
- Ponatinib, a drug that is Food and Drug Administration (FDA) approved as a therapy for
chronic myelogenous leukemia
(CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), is a
potent inhibitor of RET kinase.
Primary Objective:
-To determine the objective overall response rate (complete response [CR] + partial response
[PR] by Response Evaluation Criteria in Solid Tumors (RECIST) to ponatinib in the treatment
of patients with advanced or metastatic MTC previously treated with cabozantinib and
vandetanib who: 1) have tumors with RET mutations and 2) have tumors without RET mutations.
Eligibility:
- Patients must have histologically confirmed, unresectable, locally advanced or
metastatic MTC, with measurable disease by RECIST criteria.
- Patients must have disease amenable to biopsy and be willing to undergo biopsy for
molecular analysis, and also have adequate archival material from their thyroidectomy or
from a tumor biopsy obtained prior to beginning any systemic therapy.
- Patients must have failed or been intolerant to prior treatment with both cabozantinib
and vandetanib.
- The last dose of prior systemic therapy must be more than 28 days prior to the first
dose of ponatinib
- Radiation therapy is permitted if the last treatment was received more than 28 days
prior to the first dose of ponatinib.
Design:
- Open label phase II trial with 2 treatment groups:
- RET mutation positive MTC, previously treated with vandetanib and cabozantinib
- RET mutation negative MTC, previously treated with vandetanib and cabozantinib
- Patients will receive ponatinib 30 mg orally daily until disease progression or until
the development of intolerable side effects.
- Tumor response will be assessed by RECIST 1.1 criteria at 8 weeks and then every 12
weeks thereafter. After one year on study, tumor response will be assessed every 16
weeks.
- Patients will have a biopsy of their MTC for molecular analysis prior to initiating
treatment with ponatinib. Patients will also have a biopsy of their MTC at the time of
tumor progression, should that occur.
Title
- Brief Title: Ponatinib for Advanced Medullary Thyroid Cancer
- Official Title: A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Clinical Trial IDs
- ORG STUDY ID:
130108
- SECONDARY ID:
13-C-0108
- NCT ID:
NCT01838642
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| Ponatinib | | RET mutation negative participants |
Purpose
Background:
- Medullary thyroid cancer (MTC) represents 5% of thyroid cancers and presents as a
hereditary (25% of cases) or sporadic (75% of cases) neuroendocrine malignancy.
- MTC arises from the parafollicular C-cells of the thyroid.
- Germline mutations in the rearranged during transfection (RET) proto-oncogene occur in
virtually all of hereditary MTC cases, and somatic RET mutations occur in 50% of
sporadic cases.
- Drugs targeting RET kinase such as vandetanib and cabozantinib have shown efficacy in
the treatment of advanced or metastatic MTC, however, more effective RET inhibitors are
needed for previously untreated patients as well as patients who have become refractory
to other molecular targeted therapeutics (MTTs).
- Ponatinib, a drug that is Food and Drug Administration (FDA) approved as a therapy for
chronic myelogenous leukemia
(CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), is a
potent inhibitor of RET kinase.
Primary Objective:
-To determine the objective overall response rate (complete response [CR] + partial response
[PR] by Response Evaluation Criteria in Solid Tumors (RECIST) to ponatinib in the treatment
of patients with advanced or metastatic MTC previously treated with cabozantinib and
vandetanib who: 1) have tumors with RET mutations and 2) have tumors without RET mutations.
Eligibility:
- Patients must have histologically confirmed, unresectable, locally advanced or
metastatic MTC, with measurable disease by RECIST criteria.
- Patients must have disease amenable to biopsy and be willing to undergo biopsy for
molecular analysis, and also have adequate archival material from their thyroidectomy or
from a tumor biopsy obtained prior to beginning any systemic therapy.
- Patients must have failed or been intolerant to prior treatment with both cabozantinib
and vandetanib.
- The last dose of prior systemic therapy must be more than 28 days prior to the first
dose of ponatinib
- Radiation therapy is permitted if the last treatment was received more than 28 days
prior to the first dose of ponatinib.
Design:
- Open label phase II trial with 2 treatment groups:
- RET mutation positive MTC, previously treated with vandetanib and cabozantinib
- RET mutation negative MTC, previously treated with vandetanib and cabozantinib
- Patients will receive ponatinib 30 mg orally daily until disease progression or until
the development of intolerable side effects.
- Tumor response will be assessed by RECIST 1.1 criteria at 8 weeks and then every 12
weeks thereafter. After one year on study, tumor response will be assessed every 16
weeks.
- Patients will have a biopsy of their MTC for molecular analysis prior to initiating
treatment with ponatinib. Patients will also have a biopsy of their MTC at the time of
tumor progression, should that occur.
Detailed Description
Background:
- Medullary thyroid cancer (MTC) represents 5% of thyroid cancers and presents as a
hereditary (25% of cases) or sporadic (75% of cases) neuroendocrine malignancy.
- MTC arises from the parafollicular C-cells of the thyroid.
- Germline mutations in the rearranged during transfection (RET) proto-oncogene occur in
virtually all of hereditary MTC cases, and somatic RET mutations occur in 50% of
sporadic cases.
- Drugs targeting RET kinase such as vandetanib and cabozantinib have shown efficacy in
the treatment of advanced or metastatic MTC, however, more effective RET inhibitors are
needed for previously untreated patients as well as patients who have become refractory
to other molecular targeted therapeutics (MTTs).
- Ponatinib, a drug that is Food and Drug Administration (FDA) approved as a therapy for
chronic myelogenous leukemia
(CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), is a
potent inhibitor of RET kinase.
Primary Objective:
-To determine the objective overall response rate (complete response [CR] + partial response
[PR] by Response Evaluation Criteria in Solid Tumors (RECIST) to ponatinib in the treatment
of patients with advanced or metastatic MTC previously treated cabozantinib and vandetanib
who: 1) have tumors with RET mutations and 2) have tumors without RET mutations.
Eligibility:
- Patients must have histologically confirmed, unresectable, locally advanced or
metastatic MTC, with measurable disease by RECIST criteria.
- Patients must have disease amenable to biopsy and be willing to undergo biopsy for
molecular analysis, and also have adequate archival material from their thyroidectomy or
from a tumor biopsy obtained prior to beginning any systemic therapy.
- Patients must have failed or been intolerant to prior treatment with both cabozantinib
and vandetanib.
- The last dose of prior systemic therapy must be more than 28 days prior to the first
dose of ponatinib.
- Radiation therapy is permitted if the last treatment was received more than 28 days
prior to the first dose of ponatinib.
Design:
- Open label phase II trial with 2 treatment groups:
- RET mutation positive MTC, previously treated with vandetanib and cabozantinib
- RET mutation negative MTC, previously treated with vandetanib and cabozantinib
- Patients will receive ponatinib 30 mg orally daily until disease progression or until
the development of intolerable side effects.
- Tumor response will be assessed by RECIST 1.1 criteria at 8 weeks and then every 12
weeks thereafter. After one year on study, tumor response will be assessed every 16
weeks.
- Patients will have a biopsy of their MTC for molecular analysis prior to initiating
treatment with ponatinib. Patients will also have a biopsy of their MTC at the time of
tumor progression, should that occur.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| RET mutation positive participants | Active Comparator | Rearranged during transfection (RET) mutation positive | |
| RET mutation negative participants | Active Comparator | Rearranged during transfection (RET) mutation negative | |
Eligibility Criteria
- INCLUSION CRITERIA:
- Diagnosis of localized or metastatic unresectable medullary thyroid cancer (MTC). The
histological diagnosis of MTC must be confirmed on review of submitted tumor tissue by
the Laboratory of Pathology in the National Cancer Institute
- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (longest diameter to be recorded for non-nodal lesions and
short axis for nodal lesions) as greater than or equal to 20 mm with conventional
techniques or as greater than or equal to 10 mm with spiral computed tomography (CT)
scan.
- Disease amenable to biopsy and agree to undergo biopsy for molecular analysis
- The last dose of previous therapy targeting rearranged during transfection (RET)
kinase must be given at least 4 weeks prior to the first dose of ponatinib.
- Previous treatment with cytotoxic chemotherapy, immunotherapy, or radiotherapy are
permitted, if the last dose was given at least 4 weeks prior to the first dose of
ponatinib
- Patient must have failed (progressed on or been intolerant of) prior treatment with
cabozantinib and vandetanib.
- Age greater than or equal to 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
- Normal organ and marrow function as defined below:
- Leukocytes greater than or equal to microL
- Absolute neutrophil count 1,500/microL
- Platelet count greater than or equal to 100,000 microL
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- Aspartate aminotransferase (AST) serum glutamic oxaloacetic
transaminase(SGOT)/alanine aminotransferase (ALT) serum glutamic pyruvic
transaminase (SGPT) < 2.5 times institutional ULN or < 5 times ULN if liver
involvement
- Prothrombin Time < 1.5 times ULN
- Creatinine < 1.5 times ULN
- Lipase less than or equal to 1.5 times ULN
- Negative pregnancy test for women of childbearing potential. The effects of ponatinib
on the developing human fetus are unknown. For this reason, women of childbearing
potential and men must agree to use adequate contraception (hormonal or barrier method
of birth control; abstinence) prior to study entry and for the duration of study
participation. Should a woman become pregnant or suspect she is pregnant while she or
her partner is participating in this study, she should inform her treating physician
immediately.
- Normal QT interval corrected (Fridericia) (QTcF) on screening electrocardiogram (ECG)
evaluation, defined as QTcF of less than or equal to 450 ms in males or less than or
equal to 470 ms in females.
- Ability to understand and the willingness to sign a written informed consent document
and follow the guidelines of the clinical protocol including visits to National Cancer
Institute (NCI), Bethesda, Maryland for treatment and follow up visits.
EXCLUSION CRITERIA:
- Patients who are receiving any other investigational agent.
- Patients with brain metastases or spinal cord compression unless they completed
radiation therapy greater than or equal to 4 weeks prior to the first dose of
ponatinib and are stable without steroids or anti-convulsant therapy for greater than
or equal to 10 days.
- Medications that are known to be associated with Torsades de Pointes.
- Uncontrolled hypertension (systolic blood pressure > 150 or diastolic blood pressure >
100
- Significant or active cardiovascular disease, specifically including but not
restricted to:
- History of myocardial infarction
- History of atrial or ventricular arrhythmia
- Unstable angina within 6 months prior to first dose of ponatinib
- History of congestive heart failure
- Left ventricular ejection fraction fraction (LVEF) less than lower limit of
normal
- History of peripheral arterial occlusive disease
- History of cerebrovascular accident or transient ischemic attack
- Venous thromboembolism including deep venous thrombosis or pulmonary embolism
within 6 months prior to enrollment
- A history of pancreatitis or alcohol abuse
- Uncontrolled hypertriglyceridemia (> 450 mg/dL)
- Major surgery (with the exception of minor surgical procedures, such as catheter
placement or tumor biopsy) within 28 days prior to the first dose of ponatinib
- Ongoing or active infection including known history of human immunodeficiency virus
[HIV], hepatitis B virus [HBV], or hepatitis C virus[HCV]. Testing for these viruses
is not required in the absence of a history of infection.
- Suffer from any condition or illness that, in the opinion of the investigator, would
compromise patient safety or interfere with the evaluation of the safety of the study
drug
- Evidence of a bleeding diathesis that cannot be corrected with standard therapy or
factor replacement
- Presence of another primary malignancy within the past 2 years (except for nonmelanoma
skin cancer or cervical cancer in situ. Prior prostate cancer is also permitted if
prostatic specific antigen (PSA) is now undetectable.)
- Pregnant or lactating
| Maximum Eligible Age: | 99 Years |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Overall Response Rate. |
| Time Frame: | 2-4 months |
| Safety Issue: | |
| Description: | Defined as the percentage of participants with a best response (complete response (CR) + partial response (PR)) recorded from the start of the treatment until disease progression/recurrence assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (Whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. |
Secondary Outcome Measures
| Measure: | Progression Free Survival |
| Time Frame: | 2-4 months |
| Safety Issue: | |
| Description: | Progression free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. |
| Measure: | Number of Participants With Adverse Events |
| Time Frame: | 17 months and 19 days |
| Safety Issue: | |
| Description: | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. |
| Measure: | Molecular Differences in Advanced Medullary Thyroid Cancer (MTC) |
| Time Frame: | Prior to the first dose of ponatinib |
| Safety Issue: | |
| Description: | Compare the molecular profile of tumor deoxyribonucleic acid (DNA) prior to treatment with the molecular profile at the time of progression. Prior to the first dose of ponatinib and at time of progression, subjects were to undergo a biopsy of the primary tumor or any metastatic site for analysis of tumor DNA for rearranged during transfection (RET) or rat sarcoma (RAS) mutation. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% decrease in the sum of diameters of target lesions, taking as reference the smallest sum on study. |
| Measure: | Changes in Serum Levels of MTC Tumor Markers Calcitonin (CTN) and Its Relation With Clinical Response |
| Time Frame: | Baseline to 4 weeks |
| Safety Issue: | |
| Description: | Responders are those subjects with a best biomarker response of complete response (CR) or partial response (PR) and who achieve a clinical response of CR or PR assessed by the following criteria. Biomarker: complete response (CR) is normalization (</= upper limit of normal (ULN)) of CTN (i.e., normal <10 pg/mL) following treatment, confirmed with a repeat CTN level at least 4 weeks apart. Partial response (PR) is a >/=50% decrease in the CTN level relative to baseline level, confirmed with a repeat CTN level at least 4 weeks apart. Clinical: complete response (CR) is an average of 0-2 formed stools per day for a period of at least 4 weeks. Partial response (PR) is a >50% decrease in the average stool frequency relative to baseline and a change in stool consistency from watery to loose (partially formed) for a period of at least 4 weeks. |
| Measure: | Objective Response to Ponatinib |
| Time Frame: | up to 4 cycles of treatment with ponatinib |
| Safety Issue: | |
| Description: | Objective response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (Whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Stable disease (SD) is neither shrinkage to qualify for PR nor sufficient increase to qualify for PD. |
| Measure: | Changes in Serum Levels of MTC Tumor Markers Carcinoemybryonic Antigen (CEA) and Its Relation With Clinical Response |
| Time Frame: | Baseline to 4 weeks |
| Safety Issue: | |
| Description: | Responders are those subjects with a best biomarker response of complete response (CR) or partial response (PR) and who achieve a clinical response of CR or PR assessed by the following criteria. Biomarker: complete response (CR) is normalization (</= upper limit of normal (ULN)) of CTN (i.e., normal 0-2.5 mcg/L) following treatment, confirmed with a repeat CEA level at least 4 weeks apart. Partial response (PR) is a >/=50% decrease in the CEA level relative to baseline level, confirmed with a repeat CEA level at least 4 weeks apart. Clinical: complete response (CR) is an average of 0-2 formed stools per day for a period of at least 4 weeks. Partial response (PR) is a >50% decrease in the average stool frequency relative to baseline and a change in stool consistency from watery to loose (partially formed) for a period of at least 4 weeks. |
| Measure: | Overall Survival |
| Time Frame: | up to 6 months |
| Safety Issue: | |
| Description: | Overall survival is defined as the time between the first day of treatment to the day of disease progression. |
Details
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Terminated |
| Lead Sponsor: | National Institutes of Health Clinical Center (CC) |
Trial Keywords
- Monoclonal Antibody
- AP24534
- RET Mutation Positive
- RET Mutation Negative
- RET Inhibitor
Last Updated
February 15, 2017
